Accessibility StatementSkip Navigation NEW YORK, Oct. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marex Group plc (NASDAQ: MRX). Shareholders who purchased shares of MRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marex-group-plc-loss-submission-form/?id=174491&f ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Fluor (FLR) To Contact Him Directly To Discuss Their Options If you purchased or acquired Fluor securities between February 18, 2025 and July 31, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Ea ...

Core Viewpoint - A class action lawsuit has been filed against V.F. Corporation (VFC) for allegedly making materially false and misleading statements regarding its turnaround plans and the Vans brand's revenue growth trajectory [3][8]. Allegation Details - Defendants allegedly provided overly positive statements about VFC's turnaround plans while concealing adverse facts about the true state of those plans [3]. - It is claimed that significant reset actions were necessary to return the Vans brand to growth, which were not disclosed, leading to setbacks in revenue growth [3]. - The public commentary on the Reinvent initiative and Vans turnaround progress did not caution about these setbacks, making the statements materially false and misleading [3]. - As a result, shareholders purchased VFC's securities at artificially inflated prices due to these misleading statements [3]. Next Steps - Investors who purchased VFC shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 11, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tronox Holdings PLC, (“Tronox” or the "Company") (NYSE: TROX) investors off a class action on behalf of investors that bought securities between February 12, 2025 and July 30, 2025, inclusive (the “Class Period”). Tronox investors have until November 3, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal ri ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of NuScale Power Corporation regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - Citigroup downgraded NuScale from Neutral/High Risk to Sell/High Risk on October 21, 2025, citing competition from new entrants and the lack of a binding customer contract [2] - Following the downgrade, NuScale's stock price fell by $9.49 per share, or 21.47%, closing at $34.72 per share on October 22, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Alector, Inc. following disappointing clinical trial results for its drug, latozinemab, which did not meet primary endpoints [1][2]. Group 1: Company Overview - Alector, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases [2]. - The company recently announced results from the Phase 3 INFRONT-3 clinical trial for latozinemab, which targets frontotemporal dementia due to a progranulin gene mutation [2]. Group 2: Clinical Trial Results - The Phase 3 clinical trial results indicated that latozinemab failed to meet its clinical co-primary endpoint of slowing the progression of frontotemporal dementia [2]. - Secondary and exploratory endpoints, including fluid biomarkers and volumetric magnetic resonance imaging (vMRI), showed no treatment-related effects [2]. Group 3: Market Reaction - Following the announcement of the trial results, Alector's stock price dropped by $1.60 per share, representing a decline of 49.84%, closing at $1.61 per share on October 22, 2025 [2].

Shareholders who purchased shares of SMLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. Accessibility StatementSkip Navigation NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Semler Scientific, Inc. (NASDAQ: SMLR). CONTACT: The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protec ...

Core Viewpoint - A class action lawsuit has been filed against Semler Scientific, Inc. for allegedly making false and misleading statements regarding a material investigation by the U.S. Department of Justice related to the False Claims Act, which has resulted in investor losses [3][7]. Allegation Details - The lawsuit claims that Semler Scientific failed to disclose a significant investigation by the DOJ into potential violations of the False Claims Act while discussing such violations in hypothetical terms [3]. - As a result of these omissions, the public statements made by the defendants were materially false and misleading throughout the relevant period [3]. Next Steps for Investors - Investors who purchased Semler shares between March 10, 2021, and April 15, 2025, and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28th [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance, leading to investor losses during the specified Class Period [3][7]. Allegation Details - The lawsuit claims that LifeMD's defendants overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [3]. - It is alleged that the defendants' statements about LifeMD's business operations and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 27, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with the U.S. Department of Defense's Transportation Command, leading to investor losses during the specified class period [3][7]. Allegation Details - The complaint alleges that KBR was aware of concerns from TRANSCOM about HomeSafe's ability to fulfill its Global Household Goods Contract for several months but failed to disclose this information [3]. - KBR allegedly misled investors by claiming that its partnership with TRANSCOM would continue to grow despite these concerns [3]. - The company's public statements during the class period are claimed to be false and materially misleading, resulting in damages to investors when the truth was revealed [3]. Next Steps - Investors who purchased KBR shares between May 6, 2025, and June 19, 2025, and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].